Scientific evidence linking vitamin D with various cancer types is growing, but the effects of vitamin D on ovarian cancer stem cell-like cells (CSCs) are largely unknown. The present study aimed to examine whether vitamin D was able to restrain the stemness of ovarian cancer. A side population (SP) from malignant ovarian surface epithelial cells was identified as CSCs, in vitro and in vivo. Furthermore, 1α,25-dihydroxyvitamin D 3 [1α,25(OH) 2 D 3 ] treatment inhibited the self-renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Krüppel-like factor 4 and adenosine triphosphate binding cassette subfamily G member 2. Additionally, 1α,25(OH) 2 D 3 treatment decreased the expression of Cyclin D1, whereas it increased the expression of β-catenin and vitamin D receptor (VDR). Notably, immunofluorescence staining verified that 1α,25(OH) 2 D 3 promoted the expression of β-catenin in the cytoplasm. Furthermore, vitamin D 3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing β-catenin expressions in vivo. In conclusion, 1α,25(OH) 2 D 3 restrains the stem cell-like properties of ovarian cancer cells by enhancing the expression of VDR, by promoting the expression of β-catenin in the cytoplasm, and by suppressing the expression of CD44. These findings provide a novel insight into the functions of vitamin D in diminishing the stemness of cancer CSCs.